{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:05:04Z","timestamp":1791875104719,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Gout and diabetes mellitus type 2 (DM) frequently co-exist. The pharmacological effects of metformin may include anti-inflammatory and urate lowering effects. The objective of this study was to test these effects in patients with gout starting uric acid lowering treatment (ULT) in secondary care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective cohort study including patients with gout and DM starting ULT. Differences in the incidence density of gout flares, proportion of patients reaching target sUA in the first six months after starting ULT, and difference in mean allopurinol dose at sUA target were compared between users of metformin and users of other or no anti-diabetic drugs (control group). Correction for confounding was applied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 307 patients were included, of whom 160 (52.1%) used metformin. The incidence of flares was 1.61 and 1.70 in the first six months for respectively the metformin group and control group. The incidence rate ratio for gout flares was not significant (0.95, 95% CI 0.78 to 1.14). At six months, 62.8% and 54.9% reached target sUA in the metformin and control group respectively, corrected odds ratio of 1.09 (95% CI 0.66 to 1.80). There was no difference in mean allopurinol dose at sUA target 266\u00a0mg for metformin users and 236\u00a0mg for the control group, difference 30\u00a0mg (95% CI\u2009\u2212\u20094.7 to 65.5).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion we could not confirm a clinically relevant anti-inflammatory or urate lowering effect of metformin in patients starting ULT treatment and receiving usual care flare prophylaxis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41927-022-00261-3","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T23:02:26Z","timestamp":1653951746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of metformin use on clinical outcomes and serum urate in gout patients with diabetes mellitus: a retrospective cohort study"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-6670","authenticated-orcid":false,"given":"Frouwke","family":"Veenstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise M.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons A.","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Yee","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger L.","family":"Meek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia H. M.","family":"van den Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Flendrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"van Herwaarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"issue":"11","key":"261_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"261_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"10055","key":"261_CR3","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039\u201352.","journal-title":"Lancet"},{"issue":"9","key":"261_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/ph13090234","volume":"13","author":"T Salvatore","year":"2020","unstructured":"Salvatore T, Pafundi PC, Galiero R, Gjeloshi K, Masini F, Acierno C, et al. Metformin: a potential therapeutic tool for rheumatologists. Pharmaceuticals. 2020;13(9):234.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"261_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/1871530315666150316124019","volume":"15","author":"Y Saisho","year":"2015","unstructured":"Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets. 2015;15(3):196\u2013205.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"261_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3389\/fimmu.2018.01236","volume":"9","author":"F Ursini","year":"2018","unstructured":"Ursini F, Russo E, Pellino G, D\u2019Angelo S, Chiaravalloti A, De Sarro G, et al. Metformin and autoimmunity: a \u201cnew deal\u201d of an old drug. Front Immunol. 2018;9:1236.","journal-title":"Front Immunol"},{"issue":"5","key":"261_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/annrheumdis-2018-214656","volume":"78","author":"N Vazirpanah","year":"2019","unstructured":"Vazirpanah N, Ottria A, van der Linden M, Wichers CGK, Schuiveling M, van Lochem E, et al. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann Rheum Dis. 2019;78(5):663\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"261_CR8","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1001\/jama.1991.03470210076036","volume":"266","author":"F Facchini","year":"1991","unstructured":"Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008\u201311.","journal-title":"JAMA"},{"issue":"12","key":"261_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1517\/14728222.2012.723694","volume":"16","author":"AN Sim\u00e3o","year":"2012","unstructured":"Sim\u00e3o AN, Lozovoy MA, Dichi I. The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opin Ther Targets. 2012;16(12):1175\u201387.","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"261_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0895-7061(02)02953-9","volume":"15","author":"S Tsunoda","year":"2002","unstructured":"Tsunoda S, Kamide K, Minami J, Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens. 2002;15(8):697\u2013701.","journal-title":"Am J Hypertens"},{"issue":"1","key":"261_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12944-019-1031-6","volume":"18","author":"YL Hou","year":"2019","unstructured":"Hou YL, Yang XL, Wang CX, Zhi LX, Yang MJ, You CG. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019;18(1):81.","journal-title":"Lipids Health Dis"},{"issue":"7","key":"261_CR12","first-page":"41","volume":"87","author":"VG Barskova","year":"2009","unstructured":"Barskova VG, Eliseev MS, Kudaeva FM, Aleksandrova EN, Volkov AV, Nasonova VA, et al. Effect of metformin on the clinical course of gout and insulin resistance. Klin Med (Mosk). 2009;87(7):41\u20136.","journal-title":"Klin Med (Mosk)"},{"issue":"4","key":"261_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4065\/mcp.2010.0575","volume":"86","author":"MT Brown","year":"2011","unstructured":"Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304\u201314.","journal-title":"Mayo Clin Proc"},{"issue":"1089","key":"261_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/postgradmedj-2015-133691","volume":"92","author":"A Collier","year":"2016","unstructured":"Collier A, Stirling A, Cameron L, Hair M, Crosbie D. Gout and diabetes: a common combination. Postgrad Med J. 2016;92(1089):372\u20138.","journal-title":"Postgrad Med J"},{"issue":"9","key":"261_CR15","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1136\/annrheumdis-2014-205337","volume":"74","author":"SG Bruderer","year":"2015","unstructured":"Bruderer SG, Bodmer M, Jick SS, Meier CR. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case\u2013control study. Ann Rheum Dis. 2015;74(9):1651\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"261_CR16","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jama.2011.163","volume":"305","author":"IJ Dahabreh","year":"2011","unstructured":"Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA. 2011;305(8):822\u20133.","journal-title":"JAMA"},{"issue":"3","key":"261_CR17","doi-asserted-by":"publisher","first-page":"302.e1","DOI":"10.1016\/j.amjmed.2011.07.033","volume":"125","author":"NR Desai","year":"2012","unstructured":"Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012;125(3):302.e1-7.","journal-title":"Am J Med"},{"issue":"10","key":"261_CR18","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","volume":"19","author":"G W\u00fcrzner","year":"2001","unstructured":"W\u00fcrzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001;19(10):1855\u201360.","journal-title":"J Hypertens"},{"issue":"2","key":"261_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14397595.2017.1318467","volume":"28","author":"J Yu","year":"2018","unstructured":"Yu J, Qiu Q, Liang L, Yang X, Xu H. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2018;28(2):339\u201344.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"261_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","volume":"77","author":"H Yamanaka","year":"2018","unstructured":"Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"261_CR21","first-page":"S13","volume":"42","author":"Classification and Diagnosis of Diabetes","year":"2019","unstructured":"Classification and Diagnosis of Diabetes. Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13-s28.","journal-title":"Diabetes Care"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-022-00261-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T23:03:16Z","timestamp":1653951796000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-022-00261-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1186\/s41927-022-00261-3","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee (Commissie Mensgebonden Onderzoek regio Arnhem-Nijmegen, 2018-4692) assessed the study and provided exemption, as ethical approval for this type of study is not required under Dutch law. Patient informed consent was sought according to Dutch law and the local rules of each participating center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}